Recursion Pharmaceuticals (RXRX) Institutional Ownership

89.06% of Recursion Pharmaceuticals' stock is owned by institutional investors. Learn more on RXRX's institutional investor holdings.

Of the 281 institutional investors that purchased Recursion Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Vanguard Group Inc. ($20.85M), Softbank Group CORP. ($14.67M), Norges Bank ($12.37M), ARK Investment Management LLC ($11.42M), State Street Corp ($11.19M), Novo Holdings A S ($10.11M), and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ($4.31M).

Institutional investors have bought a total of 54,507,941 shares in the last 24 months. This purchase volume represents approximately $227.07M in transactions.

Of the 69 institutional investors that sold Recursion Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Amova Asset Management Americas Inc. ($2.75M), Sumitomo Mitsui Trust Group Inc. ($2.75M), Softbank Group CORP. ($1.03M), Vestmark Advisory Solutions Inc. ($718.08K), Jump Financial LLC ($596.12K), Hsbc Holdings PLC ($571.56K), and UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC ($540.30K).

Institutional investors have sold a total of 12,049,656 shares in the last 24 months. This volume of shares sold represents approximately $50.15M in transactions.